Parcom Capital Acquires Viroclinics BiosciencesLeading international clinical research organisation targeting growth and expansion of expertise and services ROTTERDAM, Netherlands, August 29, 2017-- Parcom Capital has acquired the successful clinical research organisation Viroclinics Biosciences. Viroclinics believes Parcom is the perfect partner to help it realise its growth ambitions. Viroclinics employs more than 100 experts and works for clients across the world. The acquisition will give Viroclinics the opportunity to expand its fields of expertise and its portfolio of services.